Emma studied biochemistry at Imperial College London then stayed on for a Masters and PhD on her favourite topic, immunology. After almost a decade there, she braved the move out of London (a whole 12 miles south) and joined The Institute of Cancer Research to study multiple myeloma, a white blood cell cancer. She left the lab for the final time in 2010 and, after a couple of years at Breakthrough Breast Cancer, joined the Science Communications team at Cancer Research UK.
We explore how clinical trials are run, and hear from a patient about what it’s like taking part in a cancer clinical trial.
Recent research has reinforced the need for all women with ovarian cancer to receive genetic testing, but they aren’t. We explore why.
Our scientists have revealed how a targeted skin cancer drug works, which could help tackle drug resistance.
Read about how we’re approaching the challenge of understanding and treating lung, pancreatic, oesophageal cancers and brain tumours.
Discussing how the idea for a new drug can come from many different avenues.
The results of a clinical trial testing radiotherapy doses for treating prostate cancer should be good news for men.
What does the evidence say about the link between negativity, stress and cancer and electromagnetism – a treatment that made headlines this week.
After 15 years of painstaking work, a team of scientists have revealed the detailed structure of one of the molecules controlling a T cell’s fate.
Research published today in Cancer Cell might open up a way through pancreatic tumours’ defences.
We’ve announced four new awards to speed up research in our Centres, particularly for cancers where survival is still poor.